BMS‐180448, A Glyburide‐Reversible Cardioprotective Agent with Minimal Vasodilator Activity
- 1 June 1995
- journal article
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 13 (2), 123-136
- https://doi.org/10.1111/j.1527-3466.1995.tb00301.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Nocturnal Hypertension and Cardiovascular RiskJournal of Cardiovascular Pharmacology, 1994
- Thromboxane Receptor Antagonist BMS-180291, but Not Aspirin, Reduces the Severity of Pacing-Induced Ischemia in DogsJournal of Cardiovascular Pharmacology, 1994
- Cold cardioplegia and the K+ channel modulator aprikalim (RP 52891): improved cardioprotection in isolated ischemic rabbit heartsCanadian Journal of Physiology and Pharmacology, 1994
- Protective Effects of ATP-Sensitive Potassium-Channel Openers in Experimental Myocardial IschemiaJournal of Cardiovascular Pharmacology, 1994
- Cardioselective anti-ischemic ATP-sensitive potassium channel openersJournal of Medicinal Chemistry, 1993
- The Pharmacology of ATP-Sensitive Potassium ChannelsAnnual Review of Pharmacology and Toxicology, 1993
- Effects of intracoronary cromakalim on postischaemic contractile function and action potential durationCardiovascular Research, 1992
- ATP-sensitive K+ channel in the mitochondrial inner membraneNature, 1991
- The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogsCardiovascular Drugs and Therapy, 1990